[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"device-related-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:device-related-infection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100640666","the-ivcare-adaptive-platform-trial-100640666",false,"NCT07587593","The IVCare Adaptive Platform Trial","Comparative Effectiveness of Interventions to Prevent Infections and Other Complications Arising From Central Venous Access Devices: the IVCare Adaptive Platform Trial.","Core inclusion Criteria:\n\n* The patient has or requires a CVAD, including a PICC, a non-tunnelled or tunnelled CVC, or a totally implanted venous access port.\n* Patient is less than 18 years old and paediatric recruitment has not been approved at the site.\n\nSecurement Domain exclusion criteria:\n\n* Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ.\n* CLABSI diagnosed from any vascular access device currently in situ within the past 7 days or being actively treated with antimicrobials.\n* Participants with an estimated life expectancy of \\\u003C30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway.\n* Participants who have previously been randomised for the same CVAD.\n* Participants who have been randomised three times.\n* SecurAcath® cannot be applied in accordance with manufacturer instructions and local policy.\n* The participant has compromised skin integrity at the current or intended insertion site, including active infection, inflammation, erosion, ulceration, or pre-existing exit-site injury.\n\nConnectors\u002FCaps Domain exclusion criteria:\n\n* Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ.\n* CLABSI diagnosed within the past 14 days or CLABSI being actively treated with antimicrobials, associated with any vascular access device currently in situ.\n* Participants with an estimated life expectancy of \\\u003C30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway.\n* Participants who have previously been randomised for the same CVAD.\n* Participants who have been randomised three times.\n* Known or suspected hypersensitivity or a confirmed allergy to chlorhexidine or silver-containing products.\n\nCancer stratum inclusion criteria:\n\n* Confirmed diagnosis of a solid tumour OR\n* Confirmed diagnosis of a haematological malignancy. OR\n* Bone marrow failure syndrome requiring systemic therapy, immunosuppression, or haematopoietic stem cell transplantation.\n\nKidney stratum exclusion criteria:\n\n• Confirmed diagnosis of kidney disease.","ALL",{"count":18,"type":19},2500,"ESTIMATED","INTERVENTIONAL",[22],"NA","The IVCare trial is a multicentre adaptive platform study evaluating interventions to prevent infections and other complications associated with central venous access devices (CVADs) in patients with newly inserted or existing devices. The study is organised into domains addressing different aspects of CVAD care and includes patient groups referred to as strata. Domains, strata and interventions may change over time as the study progresses. IVCare also includes an observational cohort study in which patients with CVADs are followed to assess CVAD care practices, infections, and other CVAD-related complications across health services.\n\nThe trial starts with two domains. The Connectors\u002FCaps Domain compares antimicrobial chlorhexidine-containing connectors and caps with standard-of-care connectors and caps used in Australian hospitals. In the cancer stratum, participants are randomised to receive either InVision-Plus CS® or standard-of-care connectors\u002Fcaps. In the kidney disease stratum, participants are randomised to receive either ClearGuard™ HD or standard-of-care connectors\u002Fcaps. Following a predefined stopping decision for ClearGuard™ HD in the kidney disease stratum, Tego™ will be introduced and evaluated in this group.\n\nThe Securement Domain compares the effectiveness of SecurAcath®, a subcutaneous anchor securement system, with standard-of-care securement methods used in Australian hospitals. Participants in both the cancer and kidney disease strata are randomised to receive either SecurAcath® or standard-of-care securement.",[25,26,27,28],"Device Related Infection","Vascular Access Complication","Device Related Sepsis","Catheter Infection",[30,31,32,33,34,35],"Central venous access device","Chlorhexidine cap","Chlorhexidine connector","Subcutaneous anchor","Central line-associated blood stream infection","Adaptive platform trial","NOT_YET_RECRUITING","2026-05-07",{"date":39,"type":40},"2026-05-14","ACTUAL",{"date":42,"type":19},"2026-12-01",{"date":44,"type":19},"2031-12-01",{"name":46,"class":47},"The University of Queensland","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":20,"phases":59,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100594451","chlorhexidine-caps-for-clabsi-prevention-in-hemodialysis-a-pilot-randomized-controlled-trial-100594451","NCT07019610","Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial","Evaluation of Chlorhexidine Caps for Central Line Associated Blood Stream Infection Prevention in People Needing Hemodialysis: a Pilot Randomised Control Trial","ECHO-HD","Inclusion Criteria:\n\n* Age≥18\n* Able to provide informed consent\n* Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)\n* 21 days BSI free\n* No known allergy to chlorhexidine and\u002For nylon and\u002For polypropylene.\n\nExclusion Criteria:\n\n* Current CLABSI\n* Known allergic to chlorhexidine and\u002For nylon and\u002For polypropylene.\n* Patients on an end-of-life pathway\n* People with a cognitive impairment and\u002For intellectual disability","18 Years",{"count":58,"type":19},60,[22],"The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service.\n\nThe main questions to answer are:\n\n* Study Feasibility\n* Occurrence of infectious complications related to renal central venous catheters\n\nParticipants will be randomly allocated to receive either of the below hemodialysis caps to cover their hemodialysis catheter hub:\n\n* The standard hemodialysis cap used at the Royal Brisbane and Women's Hospital, or\n* The intervention hemodialysis cap containing chlorhexidine inside it\n\nResearchers will compare standard and chlorhexidine hemodialysis caps to see if the presence of chlorhexidine improves the occurrance of infectious complications related to the hemodialysis catheter.",[26,25,27,28,62,63,64,65,66,67],"Catheter Complications","Catheter-Related Infections","Catheter Related Complications","Hemodialysis Catheter Infection","Hemodialysis Catheter-associated Infection","Hemodialysis Complication",[69,70,71,72,73,31,74,75,76,77],"Hemodialysis Catheter","Randomised Controlled Trial","Antimicrobial Barrier Caps","Vascular access device","Hemodialysis catheter caps","Central Venous Catheter","CVC","CLABSI","Central Line Associated Blood Stream Infection","2026-04-27",{"date":80,"type":40},"2026-04-29",{"date":82,"type":19},"2026-06",{"date":84,"type":19},"2028-02",{"name":46,"class":47},1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":16,"minAge":56,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":20,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":86},"100627858","phase-4-application-of-radiomics-for-diagnosis-and-follow-up-of-cardiovascular-device-infections-predict-study-100627858","NCT07454096","Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study","Application of Radiomics in Molecular Imaging (18F-FDG-PET\u002FCT) for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study","PREDICT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Implanted cardiovascular device (prosthetic valve, TAVI, CIED, vascular graft\u002Fendograft).\n* For infected cohorts: patients studied by FDG-PET with definitive diagnosis of CVDI based on multidisciplinary evaluation.\n* For control group: no clinical suspicion of infection at time of inclusion.\n* Written Informed consent provided (prospective cohort and control group).\n* Women of child-bearing potential must have a negative pregnancy test in serum or urine before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence (only if refraining from heterosexual intercourse during the period of twelve months of duration of the study).\n\nExclusion Criteria:\n\n* Inability to undergo FDG-PET due to contraindications (e.g., allergies, claustrophobia).\n* Pregnancy or breastfeeding.\n* Incomplete clinical data or lack of access to imaging studies.\n* Refusal or withdrawal of informed consent (for control and prospective cohort).",true,"84 Years",{"count":98,"type":19},200,[100],"PHASE4","Single center, open-label, phase IV clinical trial to study the application of radiomics in molecular imaging for diagnosis and follow-up of CVDIs. The study will include three populations:\n\n* Retrospective cohort (2018-2025)\n* Prospective cohort (2026-2027)\n* Control group (prospective)",[103,25],"Cardiac Disease","2026-03-02",{"date":106,"type":40},"2026-03-06",{"date":108,"type":19},"2026-04-30",{"date":110,"type":19},"2028-04-30",{"name":112,"class":47},"Fundacion Clinic per a la Recerca Biomédica"]